Literature DB >> 21957862

Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge.

Marina A Dobrovolskaia1, Anil K Patri, Timothy M Potter, Jamie C Rodriguez, Jennifer B Hall, Scott E McNeil.   

Abstract

AIMS: Thrombogenicity associated with the induction of leukocyte procoagulant activity (PCA) is a common complication in sepsis and cancer. Since nanoparticles are increasingly used for drug delivery, their interaction with coagulation systems is an important part of the safety assessment. The purpose of this study was to investigate the effects of nanoparticle physicochemical properties on leukocyte PCA, and to get insight into the mechanism of PCA induction. MATERIALS &
METHODS: A total of 12 formulations of polyamidoamine (PAMAM) dendrimers, varying in size and surface charge, were studied in vitro using recalcification time assay.
RESULTS: Irrespective of their size, anionic and neutral dendrimers did not induce leukocyte PCA in vitro. Cationic particles induced PCA in a size- and charge-dependent manner. The mechanism of PCA induction was similar to that of doxorubicin. Cationic dendrimers were also found to exacerbate endotoxin-induced PCA.
CONCLUSION: PAMAM dendrimer-induced leukocyte PCA depends on particle size, charge and density of surface groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21957862     DOI: 10.2217/nnm.11.105

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  19 in total

1.  Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

Authors:  Rachael M Crist; Jennifer Hall Grossman; Anil K Patri; Stephan T Stern; Marina A Dobrovolskaia; Pavan P Adiseshaiah; Jeffrey D Clogston; Scott E McNeil
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 2.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

3.  Formulation of Biocompatible Targeted ECO/siRNA Nanoparticles with Long-Term Stability for Clinical Translation of RNAi.

Authors:  Nadia R Ayat; Zhanhu Sun; Da Sun; Michelle Yin; Ryan C Hall; Amita M Vaidya; Xujie Liu; Andrew L Schilb; Josef H Scheidt; Zheng-Rong Lu
Journal:  Nucleic Acid Ther       Date:  2019-05-28       Impact factor: 5.486

Review 4.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  J Control Release       Date:  2013-06-03       Impact factor: 9.776

5.  Nanoparticle physicochemical properties determine the activation of intracellular complement.

Authors:  Anna N Ilinskaya; Ankit Shah; Alan E Enciso; King C Chan; Jan A Kaczmarczyk; Josip Blonder; Eric E Simanek; Marina A Dobrovolskaia
Journal:  Nanomedicine       Date:  2019-02-20       Impact factor: 5.307

6.  Differential Protein Adsorption and Cellular Uptake of Silica Nanoparticles Based on Size and Porosity.

Authors:  Jiban Saikia; Mostafa Yazdimamaghani; Seyyed Pouya Hadipour Moghaddam; Hamidreza Ghandehari
Journal:  ACS Appl Mater Interfaces       Date:  2016-12-06       Impact factor: 9.229

7.  Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro.

Authors:  Marina A Dobrovolskaia; Anil K Patri; Jan Simak; Jennifer B Hall; Jana Semberova; Silvia H De Paoli Lacerda; Scott E McNeil
Journal:  Mol Pharm       Date:  2011-11-10       Impact factor: 4.939

Review 8.  Current understanding of interactions between nanoparticles and the immune system.

Authors:  Marina A Dobrovolskaia; Michael Shurin; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

Review 9.  Nanoparticles and the blood coagulation system. Part II: safety concerns.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Nanomedicine (Lond)       Date:  2013-06       Impact factor: 5.307

Review 10.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.